摘要
目的探索ADRB1 Arg389Gly多态性对比索洛尔疗效的影响,为比索洛尔个体化药物治疗提供参考。方法从PubMed、Embase、Cochrane Library、中国生物医学文献服务系统、中国知网、万方等数据库系统性搜索与比索洛尔和ADRB1 Arg389Gly多态性相关的文献,检索时间为建库至2023年5月。根据研究制定的纳入与排除标准筛选、提取相关文献并进行文献质量评估。使用RevMan 5.4软件对相关结局指标进行Meta分析。结果最终纳入7项研究,共计1339人次。其中4项研究涉及比索洛尔治疗前后收缩压(SBP)和舒张压(DBP)的变化量(ΔSBP和ΔDBP),有4项研究涉及治疗前后左室射血分数(LVEF)的变化量(ΔLVEF)。研究结果显示,比索洛尔对ADRB1 Arg389Gly野生组(AA)和突变组(AG+GG)血压改善的差异均无统计学意义{ΔSBP[SMD=0.17,95%CI(-0.97,1.31),P=0.77]、ΔDBP[SMD=-0.01,95%CI(-0.65,0.62),P=0.97]};比索洛尔对两组ΔLVEF改善的差异亦无统计学意义[SMD=-0.61,95%CI(-2.74,1.53),P=0.58]。结论ADRB1 Arg389Gly多态性对比索洛尔改善心血管患者SBP、DBP和LVEF的作用无显著影响。
OBJECTIVE To explore the effects of ADRB1 Arg389Gly polymorphisms on the efficacy of bisoprolol,thus providing some information for individualized drug therapy.METHODS A systematic search was conducted in PubMed,Embase,Cochrane Library,CBM,CNKI,and Wanfang Data to retrieve and find out all relevant literature about bisoprolol and ADRB1 Arg389Gly polymorphism from the inception to May 2023.The retrieved literature was screened and selected according to the inclusive and exclusive criteria,thereafter quality assessment was conducted.RevMan 5.4 software was utilized to perform the metaanalysis for the outcome index.RESULTS Overall 7 literature with 1339 cases were included.Among them,4 studies provided the changes in systolic blood pressure(SBP),diastolic blood pressure(DBP)(ΔSBP andΔDBP);4 involving the change(ΔLVEF)of left ventricular ejection fraction(LVEF).Results of the study showed that there was no statistical significance in the improvement of blood pressure between wild-type group(AA)and mutation group(AG+GG)of ADRB1 Arg389Gly treated with bisoprolol{ΔSBP[SMD=0.17,95%CI(-0.97,1.31),P=0.77],ΔDBP[SMD=-0.01,95%CI(-0.65,0.62),P=0.97]};there was no statistical significance in the improvement ofΔLVEF[SMD=-0.61,95%CI(-2.74,1.53),P=0.58]between 2 groups.CONCLUSIONS ADRB1 Arg389Gly gene polymorphism has no significant influence on the improvement of SBP,DBP,and LVEF in cardiovascular patients who use bisoprolol.
作者
张天齐
李婷
张田
赵紫楠
纪立伟
ZHANG Tianqi;LI Ting;ZHANG Tian;ZHAO Zinan;JI Liwei(Dept.of Pharmacy,Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine,Chinese Academy of Medical Science/Beijing Key Laboratory of Assessment for Clinical Risk and Individual Application of Drugs,Beijing 100730,China)
出处
《中国药房》
CAS
北大核心
2024年第5期601-606,共6页
China Pharmacy
基金
国家重点研发计划项目(No.2020YFC2008305)。
作者简介
第一作者:张天齐,主管药师,博士。研究方向:临床药学、药事管理。电话:010-85133637。E-mail:ztqweather@hotmail.com;通信作者:纪立伟,主任药师,硕士。研究方向:临床药学、药物警戒。电话:010-85133637。E-mail:jlw1228@sina.com。
